This trial is active, not recruiting.

Condition metastatic clear cell renal cancer
Sponsor Queen Mary University of London
Start date July 2010
End date February 2014
Trial size 95 participants
Trial identifier NCT01512186, 2009-016675-29


The purpose of this study is to investigate if 14 weeks of pazopanib therapy prior to surgery (nephrectomy) is of benefit to patients with metastatic renal cancer. Ninety-five patients will be recruited into his study.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model case-only
Time perspective prospective

Primary Outcomes

Clinical benefit of 14 weeks of pre-operative pazopanib therapy, prior to nephrectomy using RECIST 1.1 criteria
time frame: Interim analysis after 34 patients have 12 weeks of treatment

Secondary Outcomes

Surgical complications (blood loss, post operative complications, hospital stay)
time frame: After the first 20 patients have had a nephrectomy
Overall Survival
time frame: After three years of study
Progression free survival
time frame: After all patients have progresssed
Local response of primary tumour to pazopanib
time frame: After 12 weeks of study drug

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Histopathologically confirmed clear cell carcinoma with measurable metastases on CT/MRI imaging (by RECIST v1.1). Only a component of clear cell is required. - No prior systemic treatment or nephrectomy for RCC. Palliative radiotherapy is acceptable to non target lesions. - Adequate organ function as defined by the following criteria: i. Total serum bilirubin ≤1.5 x uln (patients with gilbert's disease exempt) ii. Serum transaminases (ALT) <3 x uln iii. Calculated creatinine clearance >30ml/min iv. Absolute neutrophil count (ANC) ≥1000/mm3 without growth factor support v. Platelets ≥ 75,000/mm3 - Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrolment. - Willingness and ability to comply with scheduled visits, treatment plans and laboratory tests and other study procedures - ECOG performance status of 0, 1 or 2. - 18 years or above (no upper age limit) Male or female Exclusion Criteria: - Congestive heart failure (class III or IV NYHA), myocardial infarction or coronary artery bypass graft/ stenting or stroke in the previous six months, ongoing severe or unstable arrhythmia requiring medication. - Previous treatment for renal cancer - Pregnancy or breastfeeding. Female patients must be surgically sterile, be postmenopausal, or must agree to use adequate contraception during the period of therapy. - Male patients must be surgically sterile or agree to use adequate contraception during the period of therapy. - Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would in the judgement of the investigator, impart excess risk associated with study participation or study drug administration, or which, in the judgement of the investigator, would make the patient inappropriate for entry into this study - Prolonged QT interval >480msecs or a history of prolonged QT interval >480msecs - Ongoing major gastrointestinal disease including ulcerative colitis, bleeding peptic ulcer disease or inflammatory bowel disease. - Bleeding diathesis - Current uncontrolled hypertension - Another malignancy requiring treatment within the last 5 years. Local prostate cancer not requiring hormone therapy or an asymptomatic raised PSA is acceptable.

Additional Information

Official title A Phase II Study Investigating Upfront Pazopanib In Metastatic Clear Cell Renal Cancer (Panther)
Description This is a Phase II, open label study evaluating pre-operative pazopanib treatment in previously untreated patients with metastatic clear cell renal cancer. This study follows a Simon 2 stage design Patients will take pazopanib for 14 weeks followed by a nephrectomy. The drug will continue after nephrectomy until disease progression is documented. Patients will come off study once disease progression occurs, where they will then be followed for survival. Subsequent treatment at the discretion of the treating physician will be documented. After surgery, all patients will be radiologically evaluated 8 weekly until progression. Standard radical nephrectomy with lymph node dissection will be performed on those patients who are deemed operable. The surgery can be laparoscopic or open. Those not deemed suitable for nephrectomy after 14 weeks of treatment will be offered a repeat biopsy.
Trial information was received from ClinicalTrials.gov and was last updated in June 2014.
Information provided to ClinicalTrials.gov by Queen Mary University of London.